USA flag logo/image

An Official Website of the United States Government

Osteochondral tissue repair in an ovine model using a 3D woven poly…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / STTR
Agency Tracking Number:
R41AG047014
Solicitation Year:
2013
Solicitation Topic Code:
NIA
Solicitation Number:
PA12-089
Small Business Information
CYTEX THERAPEUTICS INC.
2608 ERWIN ROAD DURHAM, NC 27715-1317
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto
Agency: HHS
Contract: 1R41AG047014-01
Award Amount: $299,744.00
 

Abstract:

DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dollars annually in the U.S. alone. It follows that any therapy that improves surgical outcomes for cartilage defects and reduces overall treatment costs will have significant clinical and economical impact. Therefore, the overall goal of this study is to evaluat an implantable, cell-free reinforcing and chondroinductive scaffold for enhancing repair of large, full-thickness cartilage lesions in a large animal model (ovine) treated with standard microfracture. This scaffold is based on a three-dimensional (3D) woven fiber scaffold made from poly(caprolactone) that we have previously demonstrated to promote and supportthe synthesis of a robust cartilaginous extracellular matrix rich in proteoglycans and type II collagen all while maintaining appropriate biomimetic mechanical properties, largely owing to the slow degradation of PCL (~5% after 2 years). We have also demonstrated the ability of this cell-free implant to remain in a critically-sized defect without the need for additional anchoring. In this study, 24 adult sheep will receive, large (~80mm2), unilateral chondral defects on right medial femoral condyles. In 12sheep, defects will be treated with standard microfracture and then covered with custom-fit 3D-woven PCL implants. The remaining 12 sheep will be treated with standard microfracture only. Sheep will be sacrificed at 12 (n=6 for each group) or 24 (n=6 for each group) weeks post-procedure. All operated joints will be radiographed immediately postoperatively, at 1 week, 2 weeks, 6 weeks, and 12 weeks in the live animals, and at the 12 and 24-week sacrifice dates. Following necropsy joints will be evaluated byCT and gross and histological semi- quantitative scoring. In addition, mechanical properties of repair tissue, the surrounding cartilage, and native cartilage from contralateral limb condyles will be analyzed via indentation testing. Data are expected to be instructive in determining if our product is able to enhance cartilage regeneration in a large osteochondral defect in terms of its gross and histological appearance as well as mechanical properties in relation to native hyaline cartilage. We have significant preliminary data to support our taking this logical next step toward evaluating the commercial potential of this approach, and we believe this study will enable us to assess the efficacy of our technology for enhancing repair and increasing the patient population for microfracture surgery, towards the goal of delaying or eliminating the need for follow-up procedures. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but is limited by decreased long-term efficacy and limited applicability in larger lesions. We will evaluate the use of an advanced three-dimensional weaving technology to produce a cell-free, reinforcing and chondroinductive implant for improving the quality and longevity of repaired focal cartilage defects in a sheep model following standard microfracture. Successful outcomes would move this technology closer to a clinical reality, potentially broadening the applicability of microfracure to patients with larger lesions that currently show limited repair.

Principal Investigator:

Bradley T. Estes
919-912-9839
bradley.estes@cytextherapeutics.com

Business Contact:

Bradley T. Estes
919-912-9839
bradley.estes@cytextherapeutics.com
Small Business Information at Submission:

CYTEX THERAPEUTICS INC.
2608 ERWIN ROAD DURHAM, NC 27715-1317

EIN/Tax ID: 120524389
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
COLORADO STATE UNIVERSITY
COLORADO STATE UNIVERSITY-FORT COLLINS
2002 Campus Delivery - Sponsored Programs 601 S Howes St, Ste 408
FORT COLLINS, CO 80523-
Contact: